Cupid shares surged 13% to hit the day's high of ₹442 on the NSE following stellar Q3 earnings and a 4:1 bonus issue announced on Thursday. The contraceptives manufacturer reported a consolidated net profit of ₹33 crore in Q3FY26, which jumped 196% year on year and rose 36% sequentially. Total income in the quarter under review stood at ₹104 crore, surging 106% over the corresponding quarter of the last financial year.
The bonus issue was announced along with the company's December quarter earnings. Under the bonus issue, eligible shareholders will receive four fully paid-up equity shares for every one equity share they hold as of the record date, which the company will announce in due course. The stock witnessed significant investor interest, with over 2.5 crore shares changing hands around 1:30 pm, with the total traded value standing at ₹1,130 crore. As per latest market data, the stock is currently trading at ₹401.00 with a market capitalization of ₹10,765.53 crore.
According to reports from The Economic Times, the company's Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) soared 201% year on year while witnessing a 21% sequential uptick. The EBITDA margin in the quarter under review stood at 37%, up 1,212 bps year on year and 304 bps quarter on quarter. The board's decision to recommend the bonus issue follows a comprehensive evaluation of Cupid's capital structure, growth trajectory and shareholder base composition, designed to achieve multiple strategic objectives aligned with the company's capital allocation framework.
Chairman and Managing Director Aditya Kumar Halwasiya stated that the 4:1 bonus issue supports broader retail participation by improving affordability, while also enhancing flexibility for existing shareholders. He emphasized that it reflects the company's confidence in Cupid's growth journey and commitment to laying a strong foundation for the next phase of scale. Q3FY26 is described as the strongest quarter in the company's history, driven by steady demand and disciplined execution, with performance reflecting strength across export-led B2B operations, a scaling domestic FMCG business and improving traction in diagnostics.
